Fenofibrate

CLINICAL USE

Treatment of hyperlipidaemias types IIa, IIb, III, IV and V

DOSE IN NORMAL RENAL FUNCTION

Depends on preparation

PHARMACOKINETICS

Molecular weight :360.8

%Protein binding :99

%Excreted unchanged in urine : 0

Volume of distribution (L/kg) :0.89

half-life – normal/ESRD (hrs) :20/140–360

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20–60 134 mg daily

10 to 20 : 67 mg daily

<10 : Avoid

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Avoid

HD :Not dialysed. Avoid

HDF/high flux :Unlikely to be dialysed. Avoid

CAV/VVHD :Unlikely to be dialysed. Dose as in GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antibacterials: increased risk of myopathy with daptomycin – try to avoid concomitant use

Anticoagulants: enhances effect of coumarins and phenindione; dose of anticoagulant should be reduced by up to 50% and readjusted by monitoring INRAntidiabetics: may improve glucose tolerance and have an additive effect with insulin or sulphonylureas

Ciclosporin: ciclosporin levels appear to be unaffected; however, it is recommended that concomitant therapy should be avoided because of the possibility of elevated serum creatinine levelsLipid-regulating drugs: increased risk of myopathy in combination with statins and ezetimibe; increased risk of cholelithiasis and gall bladder disease with ezetimibe – avoid with ezetimibe

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

A few studies have noted that use of second-generation fibrates in transplant recipients is hampered by frequent rises in serum creatinineAvoid use in patients with GFR< 10 mL/min due to increased risk of rhabdomyolysis

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home